Amedisys Company Profile (NASDAQ:AMED)

About Amedisys (NASDAQ:AMED)

Amedisys logoAmedisys, Inc. is a healthcare services company. The Company's segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia. The Company's Home Health segment provides compassionate healthcare to help its patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. The Hospice segment provides support for those who are dealing with a terminal illness. The Personal care segment provides patients with assistance with the essential activities of daily living.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Home Healthcare Services
  • Sub-Industry: Health Care Services
  • Symbol: NASDAQ:AMED
  • CUSIP: 02343610
  • Web:
  • Market Cap: $1.75744 billion
  • Outstanding Shares: 33,862,000
Average Prices:
  • 50 Day Moving Avg: $50.25
  • 200 Day Moving Avg: $54.94
  • 52 Week Range: $34.58 - $65.91
  • Trailing P/E Ratio: 43.03
  • Foreward P/E Ratio: 20.55
  • P/E Growth: 1.25
Sales & Book Value:
  • Annual Revenue: $1.45 billion
  • Price / Sales: 1.18
  • Book Value: $14.54 per share
  • Price / Book: 3.46
  • EBIDTA: $105.65 million
  • Net Margins: 2.70%
  • Return on Equity: 13.71%
  • Return on Assets: 8.56%
  • Debt-to-Equity Ratio: 0.17%
  • Current Ratio: 1.21%
  • Quick Ratio: 1.21%
  • Average Volume: 395,677 shs.
  • Beta: 0.84
  • Short Ratio: 4.52

Frequently Asked Questions for Amedisys (NASDAQ:AMED)

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

How were Amedisys' earnings last quarter?

Amedisys Inc (NASDAQ:AMED) released its quarterly earnings results on Wednesday, July, 26th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.12. The firm earned $378.80 million during the quarter, compared to analyst estimates of $380.80 million. Amedisys had a net margin of 2.70% and a return on equity of 13.71%. The company's revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.42 EPS. View Amedisys' Earnings History.

When will Amedisys make its next earnings announcement?

Amedisys is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Amedisys.

Where is Amedisys' stock going? Where will Amedisys' stock price be in 2017?

8 analysts have issued twelve-month price targets for Amedisys' stock. Their predictions range from $50.00 to $60.00. On average, they expect Amedisys' stock price to reach $56.13 in the next year. View Analyst Ratings for Amedisys.

What are analysts saying about Amedisys stock?

Here are some recent quotes from research analysts about Amedisys stock:

  • 1. According to Zacks Investment Research, "Over the last month, Amedisys has steadily traded above the Zacks categorized Medical-Outpnt/Hm Care industry. Market is particularly positive on the company’s consistent and stellar Home Health division’s performance with solid organic growth in Medicare and non-Medicare revenues. We are also upbeat about the company’s initiative for strategically fit merger and acquisition activities, the most recent deal being East Tennessee Personal Care Service. The company’s strong cash position further bolsters our confidence in the stock. However, CMS’ recently proposed Home Health rule in 2017 proved grossly unfavorable for Amedisys indicating gloomy scenario ahead. Also, Escalation in operating expenses and margin contractions continue to raise concern." (5/2/2017)
  • 2. Jefferies Group LLC analysts commented, "We are excited about AMED's 2017 outlook given our view that the company's Q4 performance (margin-driven earnings beat) foreshadows accelerating realization of benefits from its recently-completed IT rollout that should translate into strong earnings power and stock upside. Additionally, AMED's strong balance sheet and robust FCF, coupled with its $100MM EBITDA deal pipeline, should translate to an active year for accretive, upside-driving acquisitions." (3/1/2017)
  • 3. Mizuho analysts commented, "Bumps? What bumps? AMED produced 4Q16 SS home health admit growth, nice margin gains and 15% upside to our adj. EBITDA estimate. For '17E, AMED seems poised to realize $40+mm in actual cost savings, admit growth in HH and continued strong growth in hospice, enough to more than offset a $17 mm hit from HH pricing to achieve EBITDA growth of 28%+ in '17E. But the not-so-cheap stock price "knows" that even though we have no guidance yet and a brand new management team. So we reset our PT at $50 to reflect market re-rating, strong results and the prospect of the real, new AMED emerging in 2017." (3/1/2017)

Who are some of Amedisys' key competitors?

Who are Amedisys' key executives?

Amedisys' management team includes the folowing people:

  • Paul B. Kusserow, President, Chief Executive Officer, Director
  • Gary D. Willis, Chief Financial Officer
  • Christopher T. Gerard, Chief Operating Officer
  • Lawrence R. Pernosky, Chief Human Resource Officer
  • Scott G. Ginn, Chief Accounting Officer
  • Michael Paul North, Chief Information Officer
  • David B. Pearce, Chief Compliance Officer
  • David L. Kemmerly, General Counsel
  • Stephen E. Seim, Chief Strategy Officer
  • Susan Sender, Chief Clinical Operations Officer

Who owns Amedisys stock?

Amedisys' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (16.30%), Vanguard Group Inc. (7.05%), FMR LLC (5.09%), William Blair Investment Management LLC (4.32%), American Century Companies Inc. (3.49%) and Wells Fargo & Company MN (3.38%). Company insiders that own Amedisys stock include Bruce D Perkins, David B Pearce, Jake L Netterville, Lawrence R Pernosky, North Tide Capital, Llc and Scott G Ginn. View Institutional Ownership Trends for Amedisys.

Who sold Amedisys stock? Who is selling Amedisys stock?

Amedisys' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Wells Fargo & Company MN, William Blair Investment Management LLC, BlackRock Inc., Voya Investment Management LLC, Goldman Sachs Group Inc., Monarch Partners Asset Management LLC and Sapience Investments LLC. Company insiders that have sold Amedisys stock in the last year include David B Pearce, Jake L Netterville, Lawrence R Pernosky and Scott G Ginn. View Insider Buying and Selling for Amedisys.

Who bought Amedisys stock? Who is buying Amedisys stock?

Amedisys' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Balyasny Asset Management LLC, TimesSquare Capital Management LLC, Timpani Capital Management LLC, Acadian Asset Management LLC, Castleark Management LLC, Foundry Partners LLC and AHL Partners LLP. View Insider Buying and Selling for Amedisys.

How do I buy Amedisys stock?

Shares of Amedisys can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amedisys' stock price today?

One share of Amedisys stock can currently be purchased for approximately $50.34.

MarketBeat Community Rating for Amedisys (NASDAQ AMED)
Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  157 (Vote Outperform)
Underperform Votes:  329 (Vote Underperform)
Total Votes:  486
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Amedisys (NASDAQ:AMED) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $56.13 (11.49% upside)

Analysts' Ratings History for Amedisys (NASDAQ:AMED)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/15/2017Oppenheimer Holdings, Inc.Reiterated RatingBuy$60.00LowView Rating Details
8/21/2017Bank of America CorporationInitiated CoverageNeutral -> Neutral$55.00LowView Rating Details
7/26/2017MizuhoDowngradeBuy -> Neutral$50.00HighView Rating Details
6/5/2017Royal Bank Of CanadaReiterated RatingHold$56.00LowView Rating Details
5/4/2017StephensBoost Price TargetEqual Weight$50.00 -> $54.00LowView Rating Details
5/3/2017Benchmark Co.Reiterated RatingHold -> Hold$50.00 -> $57.00HighView Rating Details
4/28/2017Jefferies Group LLCReiterated RatingBuy$57.00LowView Rating Details
1/17/2017Craig HallumSet Price TargetBuy$60.00N/AView Rating Details
9/11/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
5/16/2016Robert W. BairdReiterated RatingHoldN/AView Rating Details
1/11/2016Raymond James Financial, Inc.UpgradeUnderperform -> Market PerformN/AView Rating Details
11/6/2015Piper Jaffray CompaniesReiterated RatingNeutral$42.00 -> $45.00N/AView Rating Details
(Data available from 9/20/2015 forward)


Earnings History for Amedisys (NASDAQ:AMED)
Earnings by Quarter for Amedisys (NASDAQ:AMED)
Earnings History by Quarter for Amedisys (NASDAQ AMED)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017$0.53N/AView Earnings Details
7/26/2017Q2 2017$0.50$0.62$380.80 million$378.80 millionViewN/AView Earnings Details
5/2/2017Q1 2017$0.41$0.47$370.03 million$370.46 millionViewListenView Earnings Details
2/28/2017Q4 2016$0.39$0.44$368.14 million$366.30 millionViewN/AView Earnings Details
11/3/2016Q3$0.36$0.36$361.08 million$361.60 millionViewListenView Earnings Details
8/2/2016Q2$0.42$0.42$353.07 million$360.00 millionViewListenView Earnings Details
5/3/2016Q1$0.33$0.33$337.07 million$348.80 millionViewListenView Earnings Details
3/8/2016Q415$0.35$0.40$322.67 million$338.37 millionViewListenView Earnings Details
11/5/2015Q315$0.34$0.34$312.22 million$326.50 millionViewListenView Earnings Details
7/29/2015Q215$0.33$0.43$307.11 million$314.20 millionViewListenView Earnings Details
4/29/2015Q115$0.20$0.30$300.17 million$301.60 millionViewListenView Earnings Details
3/4/2015Q414$0.27$0.27$301.62 million$300.50 millionViewListenView Earnings Details
10/29/2014Q314$0.17$0.28$299.26 million$300.30 millionViewListenView Earnings Details
7/30/2014Q214$0.17$0.25$298.90 million$305.00 millionViewListenView Earnings Details
5/8/2014Q114($0.06)($0.07)$301.89 million$298.74 millionViewListenView Earnings Details
3/12/2014Q413($0.01)($0.05)$295.02 million$303.50 millionViewListenView Earnings Details
11/12/2013Q313$0.13$0.06$314.30 million$301.64 millionViewListenView Earnings Details
7/31/2013Q2 2013$0.10$0.06$328.02 million$313.10 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.18$0.13$361.41 million$339.20 millionViewListenView Earnings Details
3/12/2013Q4 2012$0.22$0.24$373.31 million$632.90 millionViewListenView Earnings Details
11/6/2012Q312$0.27$0.33$379.97 million$375.62 millionViewN/AView Earnings Details
8/7/2012$0.24$0.27ViewN/AView Earnings Details
5/8/2012$0.22$0.22ViewN/AView Earnings Details
2/28/2012$0.29$0.25ViewN/AView Earnings Details
11/1/2011$0.50$0.36ViewN/AView Earnings Details
8/2/2011$0.69$0.75ViewN/AView Earnings Details
4/26/2011$0.66$0.53ViewN/AView Earnings Details
2/22/2011$0.91$0.77ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Amedisys (NASDAQ:AMED)
2017 EPS Consensus Estimate: $2.03
2018 EPS Consensus Estimate: $2.52
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.40$0.42$0.41
Q2 20173$0.48$0.55$0.51
Q3 20173$0.53$0.54$0.53
Q4 20173$0.57$0.60$0.58
Q1 20182$0.54$0.58$0.56
Q2 20182$0.62$0.63$0.63
Q3 20182$0.64$0.66$0.65
Q4 20182$0.67$0.70$0.69
Q1 20191$0.68$0.68$0.68
Q2 20191$0.71$0.71$0.71
(Data provided by Zacks Investment Research)


Dividend History for Amedisys (NASDAQ:AMED)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Amedisys (NASDAQ:AMED)
Insider Ownership Percentage: 2.80%
Institutional Ownership Percentage: 96.55%
Insider Trades by Quarter for Amedisys (NASDAQ:AMED)
Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)
Insider Trades by Quarter for Amedisys (NASDAQ:AMED)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/8/2017David B PearceInsiderSell1,000$50.00$50,000.00View SEC Filing  
8/3/2017Bruce D PerkinsDirectorBuy2,000$46.60$93,200.00View SEC Filing  
5/25/2017Bruce D PerkinsDirectorBuy500$59.69$29,845.00View SEC Filing  
5/12/2017Jake L NettervilleDirectorSell10,000$60.00$600,000.00View SEC Filing  
5/10/2017Lawrence R PernoskyInsiderSell11,500$58.97$678,155.00View SEC Filing  
5/9/2017Lawrence R PernoskyInsiderSell11,500$58.78$675,970.00View SEC Filing  
5/8/2017Scott G GinnInsiderSell23,828$58.62$1,396,797.36View SEC Filing  
5/13/2016Bruce D PerkinsDirectorBuy1,000$50.21$50,210.00View SEC Filing  
5/11/2016Scott G GinnInsiderSell6,000$51.62$309,720.00View SEC Filing  
11/2/2015North Tide Capital, LlcMajor ShareholderSell277,720$39.79$11,050,478.80View SEC Filing  
10/28/2015North Tide Capital, LlcMajor ShareholderSell191,400$39.86$7,629,204.00View SEC Filing  
10/26/2015North Tide Capital, LlcMajor ShareholderSell56,400$39.32$2,217,648.00View SEC Filing  
8/18/2015Donald A WashburnDirectorSell20,000$45.51$910,200.00View SEC Filing  
3/13/2015Jeffrey D JeterInsiderSell11,264$27.02$304,353.28View SEC Filing  
3/13/2015Peter RicchiutiDirectorSell2,003$27.25$54,581.75View SEC Filing  
8/5/2014Jeffrey D JeterInsiderSell2,500$21.80$54,500.00View SEC Filing  
5/8/2014North Tide Capital, Llcmajor shareholderBuy500,000$13.90$6,950,000.00View SEC Filing  
5/1/2014North Tide Capital, Llcmajor shareholderBuy150,000$13.54$2,031,000.00View SEC Filing  
11/21/2013Kkr Asset Management Llcmajor shareholderBuy425,515$14.48$6,161,457.20View SEC Filing  
11/15/2013David BuceyGeneral CounselSell8,290$13.95$115,645.50View SEC Filing  
11/14/2013Kkr Asset Management Llcmajor shareholderBuy946,500$13.89$13,146,885.00View SEC Filing  
10/30/2013Kkr Asset Management LlcMajor ShareholderBuy29,615$15.94$472,063.10View SEC Filing  
10/22/2013Kkr Asset Management LlcMajor ShareholderBuy186,013$17.55$3,264,528.15View SEC Filing  
10/18/2013Kkr Asset Management LlcMajor ShareholderBuy12,652$17.95$227,103.40View SEC Filing  
7/3/2013Linda J HallDirectorSell1,721$10.65$18,328.65View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Amedisys (NASDAQ:AMED)
Latest Headlines for Amedisys (NASDAQ:AMED)
DateHeadline logoAMED Makes Notable Cross Below Critical Moving Average - September 19 at 8:50 PM logoBruker (BRKR) Strong on Product Launches Amid Currency Woes - September 19 at 3:49 PM logoWill Hurricanes Choke Cardiovascular (CSII) Q1 Performance? - September 19 at 3:49 PM logoWhy the Earnings Streak Will Continue for Amedisys (AMED) - September 18 at 4:12 PM logo5 MedTech Stocks to Pick for Stellar Returns - September 18 at 4:12 PM logoQ1 2019 Earnings Forecast for Amedisys Inc Issued By SunTrust Banks (AMED) - September 18 at 8:46 AM logoZacks: Brokerages Anticipate Amedisys Inc (AMED) Will Announce Earnings of $0.53 Per Share - September 18 at 4:22 AM logoAmedisys, Inc. – Value Analysis (NASDAQ:AMED) : September 15, 2017 - September 15 at 9:11 PM logoAmedisys Inc (AMED) Receives Buy Rating from Oppenheimer Holdings, Inc. - September 15 at 4:52 PM logoAmedisys Rides High on Strong Prospects Amid Margin Woes - September 14 at 4:21 PM logoFresenius Medical Opens Manufacturing Plant in Malaysia - September 14 at 4:21 PM logoAmedisys, Inc. breached its 50 day moving average in a Bearish Manner : AMED-US : September 14, 2017 - September 14 at 4:21 PM logoInovalon Holdings' ONE Platform Chosen by UnitedHealthcare - September 14 at 4:21 PM logoMedtronic Launches StealthStation Technology, Expands in ENT - September 13 at 4:58 PM logoIDEXX Laboratories Rides High on Strong CAG, Global Growth - September 13 at 4:57 PM logo5 Discounted MedTech Stocks for a Healthy Portfolio - September 12 at 4:02 PM logoTop Ranked Growth Stocks to Buy for September 11th - September 11 at 4:45 PM logoThe Corporate Hurricane: Houston CEOs Race to Mend a Battered Workforce - September 8 at 4:14 PM logoCorporate Hurricane: Houston CEOs Race to Mend a Battered Workforce - September 7 at 3:50 PM logoAmedisys Inc (AMED) Given Average Rating of "Hold" by Brokerages - September 6 at 11:01 AM logoAmedisys to Buy Intercity Home Care, Boosts Personal Care Arm - September 1 at 4:22 PM logo$388.54 Million in Sales Expected for Amedisys Inc (AMED) This Quarter - September 1 at 3:28 AM logoBRIEF-Amedisys announces definitive agreement to acquire Intercity Home Care - August 31 at 8:48 PM logoAmedisys Unit To Acquire Intercity Home Care - Quick Facts - August 31 at 8:48 PM logoAmedisys (AMED) to Acquire Intercity Home Care - August 31 at 8:48 PM logo3 Excellent Value Picks as Political Chaos Grips MedTech - August 31 at 8:48 PM logoAmedisys Announces Definitive Agreement to Acquire Intercity Home Care - August 31 at 3:43 PM logoAmedisys buys MA-based Intercity Home Care - August 31 at 8:44 AM logoAmedisys (AMED) Up 3.6% Since Earnings Report: Can It Continue? - August 29 at 4:06 PM logoHere's Why Chemed (CHE) is a Suitable Growth Pick for Now - August 28 at 3:52 PM logoHere's Why Masimo (MASI) is a Suitable Value Pick for Now - August 24 at 3:49 PM logoIs Amedisys (AMED) a Great Value Stock for Your Portfolio? - August 24 at 3:49 PM logoTabula Rasa Healthcare (TRHC) Catches Eye: Stock Up 9.5% - August 22 at 4:36 PM logoTabula Rasa Healthcare (TRHC) Catches Eye: Stock Up 9.5% - August 22 at 4:36 PM logoAmedisys Inc (AMED) Earns Neutral Rating from Analysts at Bank of America Corporation - August 21 at 12:24 PM logoAmedisys to Present at September Healthcare Conferences - August 18 at 1:58 PM logoAmedisys Clinical Programs Team Achieves National Readmissions Prevention Collaborative (NRPC) Certification - August 17 at 5:15 PM logoBullish Two Hundred Day Moving Average Cross - AMED - August 16 at 8:55 PM logo$388.54 Million in Sales Expected for Amedisys Inc (NASDAQ:AMED) This Quarter - August 14 at 8:42 AM logoAmedisys Inc (NASDAQ:AMED) Receives Consensus Rating of "Hold" from Analysts - August 12 at 12:28 PM logo$0.53 Earnings Per Share Expected for Amedisys Inc (NASDAQ:AMED) This Quarter - August 12 at 6:12 AM logoForm 4 AMEDISYS INC For: Aug 08 - August 10 at 2:08 AM logoSee what the IHS Markit Score report has to say about Amedisys Inc. - August 10 at 2:08 AM logoDavid B. Pearce Sells 1,000 Shares of Amedisys Inc (NASDAQ:AMED) Stock - August 9 at 9:32 PM logoWhy Amedisys Shares Slumped 24.6% in July - August 8 at 8:46 PM logoAmedisys Inc (NASDAQ:AMED) Rating Lowered to Sell at BidaskClub - August 5 at 11:56 PM logoAmedisys, Inc.: Prospects For Future Growth - August 5 at 2:12 AM logoAmedisys Inc (NASDAQ:AMED) Director Acquires $93,200.00 in Stock - August 3 at 10:38 PM logoAmedisys, Inc. :AMED-US: Earnings Analysis: Q2, 2017 By the Numbers : July 31, 2017 - July 31 at 3:54 PM logoFY2017 Earnings Estimate for Amedisys Inc Issued By Oppenheimer Holdings (NASDAQ:AMED) - July 31 at 8:14 AM



Amedisys (AMED) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff